November 21, 2025

Aspen Neuroscience Secures $115 Million Series C to Advance Parkinson’s Cell Therapy; IPO Considered for 2026

2 hours ago talkbio0Tagged Aspen, Bach Flower Essence, Autologous (qualifier value), Cell Therapy, Clinical Trials, Induced Pluripotent Stem Cells, IPO, manufacturing scale-up, Neuroscience discipline, Parkinson 's disease, plans, Regenerative Medicine, Series C financing

Aspen Neuroscience; Series C financing; Parkinson’s disease; cell therapy; ANPD001; autologous iPSC; clinical trials; manufacturing scale-up; IPO plans; regenerative medicine

Edgewise Therapeutics Appoints Christopher Martin to its Board of Directors

4 hours ago talkbio0Tagged Acquisition, Becker Muscular Dystrophy, board of directors, cardiovascular asset, Christopher Martin, commercial, Edgewise Therapeutics, executives, Leadership, Merck, Verona Pharma

Edgewise Therapeutics; Christopher Martin; Board of Directors; biotech executive; commercial leadership; Becker muscular dystrophy; cardiovascular asset; Verona Pharma; Merck acquisition

ViVac Pharma Appoints Keren Leshem as CEO to Advance RNA-LNP Cancer Immunotherapy

4 hours ago talkbio0Tagged Appointments, Biotechnology, CEO, Immunotherapy for cancer, Keren Leshem, Leadership, RNA-LNP, ViVac Pharma

ViVac Pharma; Keren Leshem; CEO appointment; RNA-LNP; cancer immunotherapy; leadership; biotechnology

Oncolytics Biotech Provides Update on Special Meeting of Shareholders

4 hours ago talkbio0Tagged biotech, Corporate, Government, jurisdiction, Nevada, Oncolytics, rescheduling, shareholders, shutdown, update

Oncolytics Biotech; special meeting; shareholders; rescheduling; government shutdown; jurisdiction change; Nevada; corporate update

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

4 hours ago talkbio0Tagged 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-3-indacene, Cantor, clinical-stage pharmaceutical, Inhibikase Therapeutics, Jefferies, pre-funded, Pricing, public entity

Inhibikase Therapeutics; public offering; common stock; pre-funded warrants; $100 million; Jefferies; BofA Securities; Cantor; clinical-stage pharmaceutical; pricing

Researchers Advance Toward Matching Patients with the Most Effective GLP-1 Drug for Personalized Obesity Treatment

4 hours ago talkbio0Tagged aspects of adverse effects, drug response, Genetic screening method, Glucagon-Like Peptide 1, Machine Learning, Mayo Clinic, MyPhenome, Obesity, personalized care, Precision Medicine, Prediction, Treatment Adherence

GLP-1; precision medicine; obesity; drug response prediction; genetic test; personalized care; side effects; machine learning; MyPhenome; Mayo Clinic; treatment adherence

EDAP Receives FDA 510(k) Clearance for Advanced Focal One Robotic HIFU System Enhancements

15 hours ago talkbio0Tagged algorithm, Clearance, Edap, Malignant neoplasm of prostate, Medical Devices, robotic HIFU, United States Food and Drug Administration

EDAP; FDA 510(k) clearance; Focal One; robotic HIFU; high intensity focused ultrasound; ultrasound imaging; prostate cancer treatment; AI algorithms; medical devices